Immunomodulators, antivirals (local classification). Russian development.
Updated · Methodology
The drug is promoted for these uses outside international guidelines. Each entry below is analyzed against AEMPS, FDA, EMA, Cochrane and major RCTs.
Not recommended
For recurrent HSV-1 and HSV-2, allokin-alfa in Russia is indicated for short courses of subcutaneous injections. The CDC and the European IUSTI/ guidelines do not list the drug. Evidence-based antiherpetics are nucleoside analogues aciclovir, valacyclovir, and famciclovir, with efficacy confirmed in large RCTs on episode duration and recurrence frequency endpoints.
Sources
ICD-10: B00 · ICD-11: 1F00.Z
Not recommended
In Russia, allokin-alfa is heavily marketed for HPV infection, which is its flagship use. There are no clinical data for alloferon in HPV specifically: no comparative studies or RCTs have been published, and the drug is absent from international and Spanish guidelines. Most HPV infections clear on their own within 1 to 2 years through the immune response. No antiviral treatment for the infection itself is proven; management rests on vaccination, cervical screening, and treatment of existing lesions such as warts or dysplasia. Allokin-alfa does not replace screening or vaccination.
Sources
ICD-10: B97.7 · ICD-11: 1A95
Not recommended
Allokin-alpha is used off-label in Russia as an immunomodulator for frequently ill people. International clinical guidelines (, , CDC, ) do not include the drug; the , , and AEMPS have not approved it. No independent international clinical studies exist. If allokin-alpha was recommended, consider seeking a second opinion.
Allokin-alfa is a synthetic oligopeptide, analogue of a cytokine inducer isolated from Calliphora vicina larvae. The manufacturer claims NK cell activation and endogenous interferon induction. Developed in Russia and registered for HSV and HPV infection in adults. , EACS, , and guidelines do not list the drug. Independent international RCTs are unavailable.
Contraindicated in pregnancy per label.
Contraindicated during breastfeeding per label.
Reference information, not a clinical decision. Discuss feeding pauses or changes with your physician or an IBCLC.
Opens the checker prefilled with this drug. Pick the second one from your regimen.
Summary of a multi-drug list →
Medicine list: everything you take in one place →
Alloferon (Allokin-alfa) is evaluated for the following indications with varying evidence strength: Immune support and respiratory infection care (evidence tier D), Human papillomavirus (HPV) (evidence tier D), Herpes simplex (evidence tier D). See the full indication matrix with dosing and citations above on this page.
Common side effects of Alloferon (Allokin-alfa) (≥ 1 in 100): Local injection site reactions, Transient fever, Headache, Weakness, malaise. See the Safety section for uncommon and serious reactions.
Contraindicated in pregnancy per label.
Contraindicated during breastfeeding per label.
Alloferon (Allokin-alfa) is contraindicated in: Pregnancy and breastfeeding; Age under 18; Autoimmune disease; Hypersensitivity. Full list in the Safety section.
Cat's claw, Sodium deoxyribonucleate (Derinat), Echinacea purpurea (juice/extract), Aminodihydrophthalazinedione sodium, Bacterial lysates OM-85, α-Glutamyl-L-tryptophan, Glucosaminyl muramyl dipeptide, Azoximer bromide